Trial reportBMC medicine2026
Utidelone in patients with advanced soft tissue sarcoma refractory to anthracycline and antiangiogenic therapy (UTISARC): a single-arm phase II study.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTreatment options remain limited for patients with advanced or metastatic soft tissue sarcoma after failure of both anthracycline-based chemotherapy and antiangiogenic therapy. Utidelone, an epothilone analog, has demonstrated antitumor activity across a broad spectrum of preclinical models and clinical trials. This single-arm, phase II trial was designed to assess the efficacy and safety of utidelone in a heavily pretreated population.
methodsThis study enrolled patients aged 18 years or older with locally advanced or metastatic soft tissue sarcoma who had previously been treated with anthracycline-based chemotherapy and antiangiogenic tyrosine kinase inhibitors. Participants received utidelone via a 90-minute intravenous infusion at a dose of 30 mg/m² on days 1-5 of each 21-day treatment cycle, continuing until disease progression or the occurrence of unacceptable toxicity. The primary endpoint was median progression-free survival. The secondary endpoints included the objective response rate, overall survival and safety.
resultsBetween August 2022 and March 2025, a total of 27 patients were included in the study. The median age was 55 years (range, 30-68). There were 15 patients with leiomyosarcoma, 3 with dedifferentiated liposarcoma, 3 with epithelioid sarcoma, 2 with angiosarcoma, and 4 with other types of sarcoma. The median number of prior systemic therapy regimens was 2 (range, 1-4). The median treatment exposure was 5 cycles (range, 1-10). Two patients achieved a partial response, resulting in an objective response rate of 7%. The median progression-free survival was 4.6 months (95% confidence interval, 3.6-5.6). Overall survival data were immature, with only 9 death events (33%) observed. The estimated 12-month overall survival rate was 80%. Most adverse events were grade 1 or 2 in severity. The most frequently observed grade ≥ 3 adverse event was peripheral neuropathy (11%).
conclusionsIn this exploratory trial, utidelone demonstrated preliminary antitumor activity and a manageable safety profile in patients with refractory soft tissue sarcoma. Further exploration of novel combination therapies involving utidelone is warranted to enhance its clinical utility.
trial registrationChiCTR2200062161, registered on July 26, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.